New trial results support treatment with Inspra within first 24 hours of symptoms in patients with acute STEMI without heart failure
10 March 2013 | By Pfizer
Results from the REMINDER trial...
List view / Grid view
News
Gilead’s Ranexa® reduces angina frequency in study of chronic angina patients with type 2 diabetes
10 March 2013 | By Gilead Sciences
Gilead Sciences announced data from the Phase 4 TERISA study...
Abbott’s minimally invasive MitraClip® system for mitral regurgitation demonstrates positive clinical and quality- of-life results for patients too high risk for surgery
10 March 2013 | By Abbott
Data from the EVEREST II study...
Results from HPS2-THRIVE study of TREDAPTIVE™ presented at American College of Cardiology Scientific Sessions
9 March 2013 | By Merck
Results from the HPS2-THRIVE study...
GSK announces regulatory submission for albiglutide in Europe
7 March 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the submission of a Marketing Authorisation Application for albiglutide...
Novo Nordisk’s award-winning NovoPen® 5 with easy-to-use memory function approved in China
7 March 2013 | By Biosector 2
NovoPen® 5 has just been approved for launch in China...
B&W Tek announces 1064nm portable Raman system
7 March 2013 | By B&W Tek
B&W Tek, Inc. is proud to announce the i-Raman® EX portable Raman spectrometer...
Roger M. Perlmutter appointed as President of Merck Research Laboratories
7 March 2013 | By Merck
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as executive vice president and president of Merck Research Laboratories (MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role…
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
6 March 2013 | By GlaxoSmithKline
24-week data from Phase III SAILING study...
FDA approves new Roche test to evaluate response to hepatitis C therapy
6 March 2013 | By Roche
Viral load test uses a novel dual-probe approach designed to manage patients being treated with antiviral therapies...
Gilead announces full 24-week Phase 2 results for once-daily single tablet HIV regimen containing novel prodrug TAF
5 March 2013 | By Gilead Sciences
TAF-based regimen now in Phase 3 development...
In Nigeria, a new project prompts easier insulin access
5 March 2013 | By Novo Nordisk
Novo Nordisk launches a new project to enhance the quality and accessibility of diabetes treatment in Nigeria...
Roche Chairman Franz B. Humer announces that he will not stand for re-election in 2014
5 March 2013 | By Roche
Roche to inform about plans for succession in autumn 2013...
Roche obtains EU approval for PERJETA
5 March 2013 | By Roche
Roche announced that the EMA has approved PERJETA (pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC)...
Pfizer presents Phase 3 safety and immunogenicity data on Prevnar 13® in adults with HIV
4 March 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
